MacroGenics (MGNX) Faces Class Action After Revealing Investigation of Patient Deaths in TAMARACK Study of Vobra Duo – Hagens Berman

SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Action Lawsuit Against MacroGenics, Inc. (MGNX): On Mar. 7, 2024, MacroGenics set investor expectations for preliminary TAMARACK data at the upcoming meeting of the American Society of Clinical Oncology ("ASCO"). Management said "[g]iven the dosing right now of 2.7 mg/kg Q4 and 2 mg/kg Q4 and with the expectations if the safety is im ...